When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AMGN - BeyondSpring's Plinabulin shows positive action in mid-stage breast cancer study
Amgen Inc.
New data from a Phase 2 clinical trial, Study 106, evaluating BeyondSpring's (BYSI+0.1%) lead drug Plinabulin compared to Amgen's (AMGN+0.1%) Neulasta (pegfilgrastim) in reducing the duration of severe neutropenia (abnormally low levels of a type of white blood cell) in certain breast cancer patients showed a positive effect. The results will be presented on March 1 at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.
More news on: BeyondSpring Inc., Amgen Inc., Healthcare stocks news,